R. Schlenk, K. Döhner, S. Mack, M. Stoppel, F. Király et al., Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A, Journal of Clinical Oncology, vol.28, issue.30, pp.4642-4650, 2010.
DOI : 10.1200/JCO.2010.28.6856

M. Verneris, S. Lee, K. Ahn, H. Wang, M. Battiwalla et al., HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research, Biology of Blood and Marrow Transplantation, vol.21, issue.10, pp.1783-1792, 2015.
DOI : 10.1016/j.bbmt.2015.05.028

N. Gorin, A. Najman, and G. Duhamel, AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN ACUTE MYELOCYTIC LEUK??MIA, The Lancet, vol.309, issue.8020, p.1050, 1977.
DOI : 10.1016/S0140-6736(77)91275-2

B. Savani, M. Labopin, N. Kröger, J. Finke, G. Ehninger et al., Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT, Haematologica, vol.101, issue.6, pp.773-80, 2016.
DOI : 10.3324/haematol.2015.138180

C. Kanakry, O. Donnell, P. Furlong, T. De-lima, M. Wei et al., Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning, Journal of Clinical Oncology, vol.32, issue.31, pp.3497-505, 2014.
DOI : 10.1200/JCO.2013.54.0625

N. Gorin, S. Giebel, M. Labopin, B. Savani, M. Mohty et al., Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects, Bone Marrow Transplantation, vol.16, issue.12, pp.1495-502, 2015.
DOI : 10.3109/10428194.2014.927453

A. Keating, G. Dasilva, W. Perez, V. Gupta, C. Cutler et al., Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research, Haematologica, vol.98, issue.2, pp.185-92, 2013.
DOI : 10.3324/haematol.2012.062059

J. Cornelissen, J. Versluis, J. Passweg, W. Van-putten, M. Manz et al., Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40???60 years, Leukemia, vol.1, issue.5, pp.1041-50, 2015.
DOI : 10.1002/bimj.4710280508

M. Mizutani, M. Hara, H. Fujita, J. Aoki, H. Kanamori et al., Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR, Bone Marrow Transplantation, vol.91, issue.5, pp.645-53, 2016.
DOI : 10.1002/ajh.23311

H. Dohner, E. Estey, and S. Amadori, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-74, 2010.
DOI : 10.1182/blood-2009-07-235358

D. Mccaffrey, B. Griffin, D. Almirall, M. Slaughter, R. Ramchand et al., A tutorial on propensity score estimation for multiple treatments using generalized boosted models, Statistics in Medicine, vol.55, issue.2, pp.3388-414, 2013.
DOI : 10.1002/sim.5753

G. Ridgeway, D. Mccaffrey, B. Griffin, and L. Burgette, Twang: toolkit for weighting and analysis of non-equivalent groups

J. Cornelissen, A. Gratwohl, R. Schlenk, J. Sierra, M. Bornhäuser et al., The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach, Nature Reviews Clinical Oncology, vol.108, issue.10, pp.579-90, 2012.
DOI : 10.1038/nrclinonc.2012.150

R. Walter, T. Gooley, B. Wood, F. Milano, M. Fang et al., Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.29, issue.9, pp.1190-1197, 2011.
DOI : 10.1200/JCO.2010.31.8121

A. Nagler, M. Labopin, N. Gorin, F. Ferrara, M. Sanz et al., Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Haematologica, vol.99, issue.8, pp.1380-1386, 2014.
DOI : 10.3324/haematol.2014.105197
URL : https://hal.archives-ouvertes.fr/hal-01325444

F. Ciceri, M. Labopin, F. Aversa, J. Rowe, D. Bunjes et al., A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation, Blood, vol.112, issue.9, pp.3574-81, 2008.
DOI : 10.1182/blood-2008-02-140095

A. Burnett, A. Goldstone, R. Stevens, R. Stevens, I. Hann et al., Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial, The Lancet, vol.351, issue.9104, pp.700-708, 1998.
DOI : 10.1016/S0140-6736(97)09214-3

P. Cassileth, D. Harrington, F. Appelbaum, H. Lazarus, J. Rowe et al., Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission, New England Journal of Medicine, vol.339, issue.23, pp.1649-56, 1998.
DOI : 10.1056/NEJM199812033392301

E. Vellenga, W. Van-putten, G. Ossenkoppele, L. Verdonck, M. Theobald et al., Autologous peripheral blood stem cell transplantation for acute myeloid leukemia, Blood, vol.118, issue.23, pp.6037-6079, 2011.
DOI : 10.1182/blood-2011-07-370247

R. Zittoun, F. Mandelli, R. Willemze, T. De-witte, B. Labar et al., Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous Leukemia, New England Journal of Medicine, vol.332, issue.4, pp.217-240, 1995.
DOI : 10.1056/NEJM199501263320403

R. Stone, S. Mandrekar, B. Sanford, S. Geyer, C. Bloomfield et al., The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial, Blood, vol.126, p.6, 2015.

J. Cornelissen, W. Van-putten, L. Verdonck, M. Theobald, J. E. Daenen et al., Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?, Blood, vol.109, issue.9, pp.3658-66, 2007.
DOI : 10.1182/blood-2006-06-025627

J. Koreth, R. Schlenk, K. Kopecky, S. Honda, J. Sierra et al., Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission, JAMA, vol.301, issue.22, pp.2349-61, 2009.
DOI : 10.1001/jama.2009.813

S. Suciu, F. Mandelli, T. De-witte, R. Zittoun, E. Gallo et al., Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial, Blood, vol.102, issue.4, pp.1232-1272, 2003.
DOI : 10.1182/blood-2002-12-3714

J. Schetelig, M. Bornhäuser, C. Schmid, B. Hertenstein, R. Schwerdtfeger et al., Matched Unrelated or Matched Sibling Donors Result in Comparable Survival After Allogeneic Stem-Cell Transplantation in Elderly Patients With Acute Myeloid Leukemia: A Report From the Cooperative German Transplant Study Group, Journal of Clinical Oncology, vol.26, issue.32, pp.5183-91, 2008.
DOI : 10.1200/JCO.2007.15.5184

V. Gupta, M. Tallman, W. He, B. Logan, E. Copelan et al., Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis, Blood, vol.116, issue.11, pp.1839-1887, 2010.
DOI : 10.1182/blood-2010-04-278317

A. Woolfrey, J. Klein, M. Haagenson, S. Spellman, E. Petersdorf et al., HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.17, issue.6, pp.885-92, 2011.
DOI : 10.1016/j.bbmt.2010.09.012

M. Michallet, M. Sobh, C. Serrier, S. Morisset, H. Labussière et al., Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings, Leukemia & Lymphoma, vol.34, issue.4, pp.999-1003, 2015.
DOI : 10.1111/j.1399-0039.2006.759_2.x

H. Greinix, I. Faé, B. Schneider, A. Rosenmayr, A. Mitterschiffthaler et al., Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors, Bone Marrow Transplantation, vol.35, issue.1, pp.57-62, 2005.
DOI : 10.1038/sj.bmt.1704741

S. Lee, J. Klein, M. Haagenson, L. Baxter-lowe, D. Confer et al., High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, vol.110, issue.13, pp.4576-83, 2007.
DOI : 10.1182/blood-2007-06-097386

N. Flomenberg, L. Baxter-lowe, D. Confer, M. Fernandez-vina, A. Filipovich et al., Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome, Blood, vol.104, issue.7, pp.1923-1953, 2004.
DOI : 10.1182/blood-2004-03-0803

M. Eapen, V. Rocha, G. Sanz, A. Scaradavou, M. Zhang et al., Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis, The Lancet Oncology, vol.11, issue.7, pp.653-60, 2010.
DOI : 10.1016/S1470-2045(10)70127-3

W. Saber, S. Opie, J. Rizzo, M. Zhang, M. Horowitz et al., Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia, Blood, vol.119, issue.17, pp.3908-3924, 2012.
DOI : 10.1182/blood-2011-09-381699

N. Gorin, M. Labopin, T. Czerw, K. Leibundgut, and D. Blaise, Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission: better outcome following busulfan and melphalan compared to busulfan and cyclophosphamide: a retrospective study from the acute leukemia working party of the EBMT, Blood, vol.126, p.926, 2015.

H. Al-ali, R. Brand, A. Van-biezen, J. Finke, M. Boogaerts et al., A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT), Leukemia, vol.18, issue.9, pp.1945-51, 2007.
DOI : 10.1182/blood-2004-02-0545

B. Cho, J. Kim, J. Yoon, S. Shin, S. Yahng et al., Superior transplantation outcomes of 8/8-matched unrelated donors as well as matched siblings to autologous transplantation for acute myeloid leukemia with intermediate cytogenetics in first remission, European Journal of Haematology, vol.2011, issue.Suppl 1, pp.365-74, 2013.
DOI : 10.1111/ejh.12089

M. Mizutani, A. Takami, M. Hara, S. Mizuno, M. Yanada et al., A Comparison of the Outcomes of Autologous and Unrelated-Donor Transplantation in Adult Intermediate-Risk Acute Myeloid Leukemia Patients in First Complete Remission, Biology of Blood and Marrow Transplantation, vol.22, issue.3, pp.30-31, 2016.
DOI : 10.1016/j.bbmt.2015.11.298

N. Gorin, M. Labopin, F. Frassoni, N. Milpied, M. Attal et al., Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation, Journal of Clinical Oncology, vol.26, issue.19, pp.3183-3191, 2008.
DOI : 10.1200/JCO.2007.15.3106

H. Fernandez, Z. Sun, M. Litzow, S. Luger, E. Paietta et al., Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin, Blood, vol.117, issue.20, pp.5306-5319, 2011.
DOI : 10.1182/blood-2010-09-309229

F. Mosna, C. Papayannidis, G. Martinelli, D. Bona, E. Bonalumi et al., Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up, American Journal of Hematology, vol.131, issue.6, pp.515-538, 2015.
DOI : 10.1002/ajh.24000

N. Gorin, M. Labopin, G. Meloni, A. Pigneux, J. Esteve et al., Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission, Haematologica, vol.98, issue.2, pp.12-16, 2013.
DOI : 10.3324/haematol.2012.064436

R. Schlenk, E. Taskesen, Y. Van-norden, J. Krauter, A. Ganser et al., The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA, Blood, vol.122, issue.9, pp.1576-82, 2013.
DOI : 10.1182/blood-2013-05-503847

T. Czerw, M. Labopin, N. Gorin, S. Giebel, D. Blaise et al., Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marr, Cancer, vol.27, issue.suppl 1, pp.1880-1887, 2016.
DOI : 10.1002/cncr.29990

M. Terwijn, W. Van-putten, A. Kelder, V. Van-der-velden, R. Brooimans et al., High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study, Journal of Clinical Oncology, vol.31, issue.31, pp.313889-97, 2013.
DOI : 10.1200/JCO.2012.45.9628

J. Cornelissen and D. Blaise, Hematopoietic stem cell transplantation for patients with AML in first complete remission, Blood, vol.127, issue.1, pp.62-70, 2016.
DOI : 10.1182/blood-2015-07-604546

H. Chakrabarty, J. Rubinger, M. Le-rademacher, J. Wang, H. Grigg et al., Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission, Biology of Blood and Marrow Transplantation, vol.20, issue.7, pp.1021-1026, 2014.
DOI : 10.1016/j.bbmt.2014.03.025

M. Wetzler, D. Watson, W. Stock, G. Koval, F. Mulkey et al., Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance), Haematologica, vol.99, issue.1, pp.111-116, 2014.
DOI : 10.3324/haematol.2013.085811

B. Savani, M. Griffith, S. Jagasia, and S. Lee, How I treat late effects in adults after allogeneic stem cell transplantation, Blood, vol.117, issue.11, pp.3002-3011, 2011.
DOI : 10.1182/blood-2010-10-263095

S. Holtan, T. Defor, A. Lazaryan, N. Bejanyan, M. Arora et al., Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation, Blood, vol.125, issue.8, pp.1333-1341, 2015.
DOI : 10.1182/blood-2014-10-609032